应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RLMD Relmada Therapeutics, Inc.
盘前交易 07-17 06:31:12 EDT
3.77
-0.07
-1.82%
最高
3.88
最低
3.77
成交量
6.39万
今开
3.83
昨收
3.84
日振幅
2.76%
总市值
1.14亿
流通市值
1.05亿
总股本
3,017万
成交额
24.37万
换手率
0.23%
流通股本
2,776万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Relmada Therapeutics Inc 预计每股亏损85美分 - 财报前瞻
Reuters · 05-08
Relmada Therapeutics Inc 预计每股亏损85美分 - 财报前瞻
美国研究综述-迪克体育用品、Nvidia、PVH
Reuters · 03-20
美国研究综述-迪克体育用品、Nvidia、PVH
Relmada Therapeutics Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 03-20
Relmada Therapeutics Inc 报告截至 12 月的季度业绩 - 收益摘要
Relmada Therapeutics Inc 预计每股亏损 83 美分 - 财报前瞻
Reuters · 03-16
Relmada Therapeutics Inc 预计每股亏损 83 美分 - 财报前瞻
暂无数据
公司概况
公司名称:
Relmada Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Relmada Therapeutics, Inc.是私人控股公司,于2004年5月注册成立。该公司是一家临床阶段的生物制药公司,致力于开发用于治疗慢性疼痛的候选药物。该公司专注于开发d-methadone(右美沙酮,REL-1017),一种N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。美沙酮是一种新的化学实体,可能解决中枢神经系统(CNS)疾病和其他疾病治疗中未满足医疗需求的领域。
发行价格:
--
{"stockData":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":3.77,"timestamp":1721160000000,"preClose":3.84,"halted":0,"volume":63870,"delay":0,"floatShares":27758959,"shares":30174202,"eps":-3.132135,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.07,"latestTime":"07-17 06:31:12 EDT","open":3.83,"high":3.8759,"low":3.77,"amount":243749.76354,"amplitude":0.027578,"askPrice":6.03,"askSize":200,"bidPrice":1.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.132135,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721223000000},"adr":0,"adjPreClose":3.77,"volumeRatio":0.23426960478593659,"impliedVol":2.1265,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/RLMD/tweets","defaultTab":"tweets","newsList":[{"id":"2433457769","title":"Relmada Therapeutics Inc 预计每股亏损85美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433457769","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433457769?lang=zh_cn&edition=full","pubTime":"2024-05-08 10:04","pubTimestamp":1715133889,"startTime":"0","endTime":"0","summary":" * Relmada Therapeutics Inc 将于5月8日公布截至2024年3月31日的财报,预计该公司的季度收入将保持不变。* * LSEG的分析师平均预计Relmada Therapeutics Inc每股亏损85美分。* 华尔街对 Relmada Therapeutics Inc 的 12 个月目标价中位数为 7.75 美元,高于其上一次收盘价 3.82 美元。5月8日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","LENZ"],"gpt_icon":0},{"id":"2420798966","title":"美国研究综述-迪克体育用品、Nvidia、PVH","url":"https://stock-news.laohu8.com/highlight/detail?id=2420798966","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420798966?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:14","pubTimestamp":1710918896,"startTime":"0","endTime":"0","summary":" 路透社3月20日 - 华尔街证券分析师周三调整了对迪克体育用品公司、英伟达和 PVH 等几家美国上市公司的评级和目标价。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTDR","BK4525","BK4588","BK4505","HLT","LU0170899867.USD","DCPH","GOCO","BK4527","BK4503","RIOT","CAL","CSCO","IE00BMPRXN33.USD","RCM","SAIC","BK4543","LU0444971666.USD","PTCT","SMPL","TNYA","CNM","LU0053671581.USD","LU0731783394.SGD","BRO","DKS","SNDX","LU0072462426.USD","BK4023","IE00BWXC8680.SGD","PVH","RLMD","RAIL","SG9999002224.SGD","TRML","BK4216","CRNX","HQY","PLNT","BBIO","NVDA","SG9999002232.USD","BK4213","LU0889565916.HKD","HPP","LU0238689110.USD","LU1430594728.SGD","BK4139","BK4212","ASO"],"gpt_icon":0},{"id":"2420785476","title":"Relmada Therapeutics Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2420785476","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420785476?lang=zh_cn&edition=full","pubTime":"2024-03-20 05:02","pubTimestamp":1710882138,"startTime":"0","endTime":"0","summary":" * Relmada Therapeutics Inc 报告,截至12月底的季度调整后每股亏损84美分,高于去年同期的每股收益1.41美元。五位分析师对该季度的平均预期是每股亏损 83 美分。华尔街预期为每股-91美分至-74美分。* Relmada Therapeutics Inc 报告的季度每股收益为亏损 84 美分。* Relmada Therapeutics Inc 的股价本季度上涨了 33.3%。华尔街对 Relmada Therapeutics Inc 的 12 个月目标价中位数为 6.75 美元。本摘要由 LSEG 3 月 19 日 09:01 p.m. UTC 数据机器生成。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2419394180","title":"Relmada Therapeutics Inc 预计每股亏损 83 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2419394180","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419394180?lang=zh_cn&edition=full","pubTime":"2024-03-16 04:32","pubTimestamp":1710534732,"startTime":"0","endTime":"0","summary":" * Relmada Therapeutics Inc 将于3月19日公布截至2023年12月31日的财报,预计该公司的季度收入将保持不变。* * LSEG的分析师平均预计Relmada Therapeutics Inc每股亏损83美分。* 目前分析师对该公司股票的平均评级为 \"买入\",建议的细分为 2 个 \"强烈买入 \"或 \"买入\",3 个 \"持有\",没有 \"卖出 \"或 \"强烈卖出\"。* 华尔街对 Relmada Therapeutics Inc 的 12 个月目标价中位数为 6.75 美元,高于其上次收盘价 5.03 美元。3月15日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.relmada.com","stockEarnings":[{"period":"1week","weight":-0.0805},{"period":"1month","weight":0.2525},{"period":"3month","weight":-0.1944},{"period":"6month","weight":0.1056},{"period":"1year","weight":0.3275},{"period":"ytd","weight":-0.0894}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.1884}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Relmada Therapeutics, Inc.是私人控股公司,于2004年5月注册成立。该公司是一家临床阶段的生物制药公司,致力于开发用于治疗慢性疼痛的候选药物。该公司专注于开发d-methadone(右美沙酮,REL-1017),一种N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。美沙酮是一种新的化学实体,可能解决中枢神经系统(CNS)疾病和其他疾病治疗中未满足医疗需求的领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047507},{"month":2,"riseRate":0.666667,"avgChangeRate":0.107392},{"month":3,"riseRate":0.5,"avgChangeRate":-0.035153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.029344},{"month":5,"riseRate":0.428571,"avgChangeRate":0.009291},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.112899},{"month":7,"riseRate":0.714286,"avgChangeRate":0.095553},{"month":8,"riseRate":0.5,"avgChangeRate":0.03989},{"month":9,"riseRate":0.833333,"avgChangeRate":0.09509},{"month":10,"riseRate":0.333333,"avgChangeRate":0.10844},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.069992},{"month":12,"riseRate":0.5,"avgChangeRate":0.132279}],"exchange":"NASDAQ","name":"Relmada Therapeutics, Inc.","nameEN":"Relmada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Relmada Therapeutics, Inc.,RLMD,Relmada Therapeutics, Inc.股票,Relmada Therapeutics, Inc.股票老虎,Relmada Therapeutics, Inc.股票老虎国际,Relmada Therapeutics, Inc.行情,Relmada Therapeutics, Inc.股票行情,Relmada Therapeutics, Inc.股价,Relmada Therapeutics, Inc.股市,Relmada Therapeutics, Inc.股票价格,Relmada Therapeutics, Inc.股票交易,Relmada Therapeutics, Inc.股票购买,Relmada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}